Investigational drug · Phase 3
Denifanstat
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acne Vulgaris.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "Denifanstat"
First trial start
2026
Oct 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Denifanstat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acne Vulgaris
Approved drugs for the same conditions: Acne · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Denifanstat" as an intervention, largest first.
- Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)Pivotal-lookingRecruiting
Sagimet Biosciences Inc.Industry
NCT07863193 · 800 participants (planned) · Start Oct 21, 2026 · Primary completion Aug 2027
Drug: Denifanstat · For: Acne Vulgaris
Sites: Bryant, Arkansas; Beverly Hills, California; Fremont, California · 35 sites in all
- A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne VulgarisPivotal-lookingCompleted
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT06192264 · 480 participants · Start Jan 23, 2024 · Primary completion May 19, 2025
Drug: ASC40 · For: Acne
Sites: Bengbu, China; Hefei, China; Wuhu, China · 41 sites in all
- A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne VulgarisPivotal-lookingCompleted
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT06248008 · 240 participants · Start Apr 18, 2024 · Primary completion Nov 12, 2025
Drug: ASC40 · For: Acne
Sites: Shanghai, China
Sagimet Biosciences Inc.Industry
NCT05835180 · 48 participants · Start May 1, 2023 · Primary completion Dec 18, 2023
Drug: TVB-2640 - 50 mg · For: Non-alcoholic Steatohepatitis; Hepatic Impairment; Cirrhosis
Sites: Orlando, Florida; San Antonio, Texas; Kistarcsa, Hungary
Sagimet Biosciences Inc.Industry
NCT07216313 · 40 participants · Start Sep 30, 2025 · Primary completion Oct 20, 2025
Drug: Denifanstat; Resmetirom · For: Healthy
Sites: Tempe, Arizona
Mayo ClinicAcademic, hospital or other
NCT03179904 · 17 participants · Start Aug 3, 2017 · Primary completion Jul 30, 2024
Drug: Anastrozole; Denifanstat and 5 more · For: Advanced Breast Carcinoma; HER2-Positive Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8 and 2 more
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASHPivotal-lookingWithdrawn
Sagimet Biosciences Inc.Industry
NCT06692283 · 0 participants · Start Mar 2025 · Primary completion Jun 2026
Drug: denifanstat; Placebo · For: MASLD; MASH; NASH and 4 more
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 FibrosisPivotal-lookingWithdrawn
Sagimet Biosciences Inc.Industry
NCT06594523 · 0 participants · Start Mar 2025 · Primary completion Dec 2030
Drug: Denifanstat; Placebo · For: MASH; NASH; Metabolic Dysfunction-associated Steatohepatitis and 3 more
Newest research
PubMed records naming it or its code names, newest first.
- Fatty acid synthase in cardiovascular disease: from molecular mechanisms to therapeutic targeting.
Ibrahim D, Zaghloul MS, Koklu B, et al. · Cardiovasc Res 2026
- Pharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates.
Syed-Abdul MM · Expert Opin Pharmacother 2026
- A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.
You Z, Yang L, Long Y, et al. · Front Pharmacol 2026
- Denifanstat in acne therapy: A promising step forward.
Guida S, Makrantonaki E · J Eur Acad Dermatol Venereol 2026
- Denifanstat for moderate-to-severe acne: A Phase 2, randomized, double-blind, placebo-controlled trial.
Chen Q, Chen R, Wu L, et al. · J Eur Acad Dermatol Venereol 2026
- Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.
Sun XY, Jiang HL, Ma YT, et al. · J Transl Med 2026
Also in development for Acne Vulgaris
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.